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Abstract
Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States.
Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating
within the ascitic fluid (peritoneal ovarian carcinomatosis). Despite aggressive surgical “debulking,” recurrence of
recalcitrant disease is frequent with poor patient survival. Efforts to improve survival rates are hindered by lack of
biomarkers that can detect and effectively treat ovarian cancer in its early stages. Urokinase plasminogen activator
receptor (uPAR) is a multifunctional receptor involved in a myriad of tumor cell processes. However, the role of host
uPAR in ovarian cancer is still elusive. To define the potential proinflammatory role of uPAR in ovarian cancer, first,
using a syngeneic murine model in uPAR−/− mice, we found that ablation of uPAR restrained tumor take and peri-
toneal implants and prolonged the survival of uPAR−/−mice compared with their uPAR+/+ counterparts. Ascitic fluid
accumulation was significantly decreased in uPAR−/− mice with decreased macrophage infiltration. Second, in vitro
mechanistic studies revealed that host uPAR is involved in the multiple steps of peritoneal metastatic cascade. Third,
we evaluated the prognostic utility of tumor and stromal uPAR in human ovarian cancer tissue microarray. In sum-
mary, our studies indicated that uPAR plays a significant role in ovarian cancer cell-stromal crosstalk and contributes
to increased vascular permeability and inflammatory ovarian cancer microenvironment. This provides a rationale for
targeting the uPAR with either specific neutralizing antibodies or targeting its downstream inflammatory effectors in
patients with ovarian cancer.
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Introduction
Ovarian cancer is the fourth leading cause of cancer death among US
women [1]. It has the highest mortality rate of all gynecologic tumors
because most patients will experience recurrences and develop chemoresis-
tant disease [1]. Unlike other invasivemetastasizing tumors, disseminated
ovarian cancer cells have predilection to peritoneal cavity where they sur-
vive as floating spheroids or implants onto peritoneal surfaces [2]. The
first step of peritoneal metastasis involves a tightly regulated multistep
process of detachment, migration, invasion of, and, proliferation on,
mesothelium-covered surfaces [2,3]. A number of factors have been im-
plicated asmediators of ovarian cancer metastasis, including proteases [4].
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The urokinase plasminogen activator receptor (uPAR) was originally
identified on the monocyte/macrophage–like human cell line U937 as
the membrane receptor for the serine protease urokinase-type plas-
minogen activator (uPA) and has since been implicated in a large
number of physiological and pathologic conditions, including cancer
invasion and metastasis [5]. In addition to mediating directed extra-
cellular proteolysis on the surface of migrating or invading cells, uPAR
also mediates cell signaling, proliferation, and survival [6–8]. Highly
endogenous intratumoral levels of both uPAR and its ligand uPA are
often present in advanced metastatic cancers (summarized in Mazar
[7]). uPAR is expressed in tumors by multiple tumor-associated cell
types including the tumor cells themselves, endothelial cells, stromal
cells and tumor-associated macrophages (TAMs) [7,9,10]. In patients
with ovarian cancer, high levels of uPA, soluble uPAR, and/or uPAR
have been detected in serum, ascites, and ovarian cancer tumors
(primary and metastatic; summarized in Kenny et al. [6]), whereas
the prognostic utility of uPAR expression in ovarian cancer tumor
tissues was not established [6]. However, mechanistic studies revealed
that targeting uPAR by a neutralizing antibody inhibited ovarian cancer
cell adhesion, invasion, and migration in vitro and reduced tumor
burden in in vivo xenografts [6].
The uPA/uPAR axis also plays a critical role in monocyte and
macrophage chemotaxis [8,11]. In the peritoneal microenvironment,
inflammatory and proteolytic factors present as a major component
and are contributed not only by invasive tumor cells but also by a
large number of infiltrating macrophages (TAMs), activated meso-
thelial cells, and endothelial cells [12–14].
uPAR, through binding to its agonist uPA, initiates plasmin-mediated
extracellular cell matrix (ECM) proteolysis, which is involved in many
processes in which cell migration occurs, including tumor cell invasion
[15] and monocyte infiltration [16]. uPA/uPAR axis has been shown to
stimulate adhesion and chemotactic movement of myeloid cells [17]
and to induce cell migration in human endothelial cells [18].
Independently of its proteolytic activity, uPAR has been shown
to interact with integrins, ECM molecules vitronectin, laminin,
and fibronectin with activation of growth factor receptors, and in-
tegrin signaling cascades that converge in cell survival, adhesion,
migration, invasion, and angiogenesis [6,11,19–21].
The involvement of uPAR in vascular endothelial growth factor
(VEGF)–induced angiogenesis and tumor cell invasiveness has been
earlier reported in meningiomas, gliomas, and glioblastomas and was
contributed by endothelial cells as well as tumor cells [19,20,22]. In ad-
dition, uPAR has been identified as a downstream effector of VEGF-
induced microvascular permeability, a process that involved VEGF
receptor 2 (VEGFR2) tyrosine phosphorylation, disruption of endothe-
lial tight junction proteins, and β-catenin nuclear translocation [23,24].
To gain insight on the multifunctional properties of the uPAR in
ovarian cancer, and given that antibody-based therapies have been
established as clinically feasible and efficacious [6], we decided to
investigate the differential effects of host uPAR in the peritoneal
microenvironment. We first used a syngeneic murine model of
ovarian cancer injecting ID8 cells [25–27] in uPAR−/− and uPAR+/+
mice [8]. We dissected the contribution of uPAR from each cell type
in vitro in primary and established human cells first to identify the
roles of host uPAR and to verify that the observed biologic functions
are specific to the molecule independent of the host background or
the long-term knockdown of the uPAR. To our knowledge, this is
the first report that demonstrates a direct link between activation of
host uPAR, TAM, and vascular permeability in ovarian cancer.
Materials and Methods
Mice
Homozygous uPAR−/− and uPAR+/+ (C57B6 background) were
from Jackson Laboratories (Bar Harbor, ME). Mice were backcrossed
on C57B6 background. uPAR deficiency does not compromise fertil-
ity or development [28]. All experimental procedures were performed
according to the approved Institutional Animal Care and Use Com-
mittee protocols of Medical College of Georgia.
In Vivo Tumor Generation and Fluorescent Stereomicroscopy
For intraperitoneal (IP) tumor generation, ID8 cells stably express-
ing GFP and GFP-VEGF [14,26] were injected in uPAR+/+ and
uPAR−/− mice (n = 15 per group). Animals were monitored twice
weekly for tumor development and survival (up to 15 weeks). Tumor
growth was determined by weekly measurements of animal girth
[14,26]. At the end of the experimental period (8 weeks), animals were
sacrificed, and organs were examined for tumor development and
spread. The gross morphology of tumor growth and the extent of
dissemination in the peritoneal cavity were observed and documented
using a fluorescent stereomicroscope equipped with Q-Imaging digital
camera (Leica Microsystems, Wetzlar, Germany) [26]. Tumor dis-
semination in the peritoneal cavity was scored on two arbitrary scales
based on the number and size of tumor nodules as earlier described
[26]. On the basis of tumor nodule size, each animal was given an
arbitrary score from 0 to +4 (0, for tumor-free animals with undetect-
able nodular growths; +1, for nodules <1 mm in diameter or those only
visualized by fluorescent stereomicroscopy; +2, for nodules 1-5 mm in
diameter, +3, for nodules 5-10 mm; and +4, for nodules >10 mm).
On the basis of the number of nodules in the peritoneal surface and
abdominal structures, another scale from 0 to +4 was set (0, for tumor
free; +1, for 0-5 nodules/examined organ, including nodules that were
only detected by fluorescent stereomicroscope; +2, for 5-10 nodules/
organ; +3, for 10-15 nodules; +4, for >20 nodules including nodular
plaques and omental caking). Results were expressed as the mean
score ± SEM for each animal. Tissues and ascitic fluid were collected
and processed as earlier described [14,26].
Cell Lines and Reagents
Human ovarian carcinoma cell lines (SKOV3, OVCAR3, and
CAOV3), human peritoneal mesothelial cell line (Meso301), murine
ovarian carcinoma cell line (ID8), and human monocytoid cell line
(U937) were obtained from ATCC (Manassas, VA) and maintained
as described previously [14,26,29,30]. Human umbilical vein endo-
thelial cells (HUVECs) were purchased from Lonza (Walkersville,
MD) and were maintained in endothelial cell growth media as per
supplier instructions. Reduced growth factor Matrigel was from BD
Biosciences (Bedford, MA). Recombinant human VEGF was from
Peprotech (Rocky Hill, NJ). Human uPAR MAb (clone 62022)
was from R&D Systems (Minneapolis, MN). Unless otherwise
stated, all other chemicals and culture media were purchased from
Sigma (St. Louis, MO) and Thermo Fisher Scientific (Fairlawn, NJ).
Transfections, Western Blot Analysis, and Gelatin Zymography
Knockdown of uPAR in mesothelial cells, HUVECs, and U937
macrophages was carried out using ON-TARGETplus SMARTpool
Human PLAUR small interfering (siRNA) oligonucleotides (Dharmacon,
Millipore, Billerica, MA) and FuGENE 6 transfection reagent (Roche,
Branchburg, NJ). The efficiency of transfection was determined
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48 hours later by harvesting cells in RIPA buffer as earlier described
[27,31,32]. Protein concentrations were determined by bicinchoninic
acid (BCA) assay (Pierce, Thermo Fisher). Cell lysates (25 μg) were re-
solved by 4% to 20% SDS-PAGE, and transferred onto polyvinylidene
fluoride (PVDF) membranes (BioRad, Hercules, CA) and probed with
the indicated antibodies. Protein detection was carried out using HRP-
conjugated secondary antibodies and SuperSignal Femto Maximum
Sensitivity Substrate (Pierce). For zymography, ascitic fluid was cleared
by centrifugation at 12,000g for 20 minutes at 4°C, 10 μg was resolved
in 10%SDS-PAGE gels containing 1mg/ml gelatin under nonreducing
conditions, and gelatinolytic activity was detected in Coomassie blue–
stained gels [26].
Luciferase Activity Assays
Mesothelial cells, HUVECs, and U937 cells (5 × 104/well of a
24-well plate) were transfected with 0.5 μg of pNFκB-Luc (Stratagene,
La Jolla, CA) using FuGENE 6, 24 hours after transfection with si
uPAR or scrambled (scr) control oligonucleotides, as per manufac-
turer’s instructions, serum starved for an additional 24 hours, and were
cocultured with the ovarian cancer cells for further 24 hours before lysis
(Glo Lysis Buffer; Promega, Madison, WI). Luciferase activity was
measured (Luciferase Assay Solution, Bright Glo; Promega) and were
normalized by measuring DNA content of cells using CyQuant cell
proliferation assay (Molecular Probes, Eugene, OR), according to the
manufacturer’s protocol.
Preparation of Conditioned Medium
Subconfluent monolayers of human ovarian cancer cells and U937
macrophages (2 × 106 cells/well), were grown in six-well plates,
serum starved in serum-free medium overnight, and were allowed
to condition for 72 hours. Conditioned media (CM) were collected
and cleared by centrifugation, filter sterilized, and added to the
bottom chambers for chemoinvasion assays.
Cytokines, Prostaglandin E2, and 8-Isoprostane ELISA and
uPA Activity
The levels of VEGF, IL-6, CCL2, and 8-isoprostane and prosta-
glandin E2 (PGE2) were determined in the ascitic fluid and CM of
different experimental conditions using appropriate species-specific
commercial kits from R&D Systems, Cayman Chemical, Inc (Ann
Arbor, MI), and RayBiotech, Inc (Norcross, GA), as per the manufac-
turer’s recommendations. uPA activity was measured by a colorimetric
assay kit (Chemicon, Millipore), according to the supplier’s guidelines.
The assay is sensitive over a range of 0.05 to 50 U of uPA activity,
which cleaves a chromogenic substrate, a tripeptide with pNA group,
forming a colored product with detectable absorbance at A405.
Adhesion and Invasion Assays
Ovarian cancer cell lines were labeled with CellTracker Green
CMFDA (5-chloromethylfluorescein diacetate; Molecular Probes,
Invitrogen) as per manufacturer’s instructions and were allowed to
adhere to confluent monolayers of Meso301 cell lines as earlier de-
scribed [14,30]. Chemoinvasion assays were carried out with 24-well
3- and 8-μm-pore-size polycarbonate filters (Costar, Corning, NY)
coated with Matrigel. Briefly, 1 × 105 cells were added to the upper
chambers of Matrigel-coated filters, and the bottom chambers were
filled with 600 μl of 72-hour CM of cancer cells or macrophages.
Chemoinvasion assays were carried out for 5 hours, at the end of
which cells that migrated to the undersurface of the filters were stained
with Diff-Quick (Fisher Scientific), and cells were counted in six
high-power fields as described earlier [14,26,27,29–32].
Immunohistochemistry of Murine Tissues and
Human Tissue Microarrays
Ki67 and F4/80 antibodies were purchased from BD Biosciences
and AbD Serotec Protein (Raleigh, NC). F4/80 and proliferation
indices were determined [26,32]. Human ovarian cancer tissue micro-
arrays (TMAs) were purchased from US Biomax (Bethesda, MD).
uPAR protein intensity and frequency were detected in human TMAs
and were blindly scored by two independent investigators. The in-
tensity of the staining was categorized from negative (−) to low (+),
intermediate (++), and high (+++). The frequency of staining was de-
termined by counting the number of positive cells divided by 100 cells.
The cutoffs of expression for prognostic evaluation were selected based
on the median values of expression among the groups under analysis
[32]. The two scoring systems were adopted because of tumor hetero-
geneity and based on the assumption that increase in intensity of uPAR
protein expression likely precedes increases in its frequency and there-
fore should have a higher weight. For each core, data were transformed
into composite expression score CES the intensity + frequency. The
range of CES was from 0 to 12 for tumor uPAR and from 0 to 4 for
stromal uPAR.
RNA Isolation and Quantitative Reverse Transcription–
Polymerase Chain Reaction
Total RNA was extracted from cultured cells RNeasy kits (Qiagen,
Valencia, CA) and quantitative reverse transcription–polymerase chain
reaction was carried out using iScript cDNA Synthesis Kit and iQ
SYBR Green SuperMix and BioRad iCycler. The primer sequences
for human VEGF were F, 5′-ctacctccaccatgccaagt-3′, and R, 5′-gcag-
tagctgcgctgataga-3′; those for human CCL2 were F, 5′-cagccagatgcaat-
caatgc-3′, and R, 5′-gcactgagatcttcctattggtgaa-3′; and those for human
IL-6 were F, 5′-ggtacatcctcgacggcatct-3′, and R, 5′-gtccctctttgctgct-
ttcac-3′. The primer sequences for GAPDH were F, 5′-agggctgcttt-
taactctggt-3′, and R, 5′-ccccacttgattttggaggga-3′. Each analysis was
performed in triplicate.
Measurement of Paracellular Flux
HUVECs (2 × 105 cells/well) were seeded on 24-well filters
(0.4 μm, 6.5-mm transparent polycarbonate filters) and allowed to
attach and form tight junctions for 48 hours in complete growth
medium. HUVECs were then shifted to serum-free medium for
24 hours then were treated with VEGF (40 ng/ml) or for 72 hours
with CM of ovarian cancer cells. The paracellular flux is measured by
adding 0.5 mg/ml fluorescein isothiocyanate–conjugated dextran
(FITC-dextran; M r = 5000; Sigma) in the apical chamber before
and after apical treatment of cells with, as well as CM of ovarian can-
cer cell lines. Measurements were made before treatment and at 1, 2,
4, and 6 hours after treatment. Transmembrane flux of dextran 5K
from apical to basal was determined by measuring the fluorescence in
the 10-μl aliquots taken from both apical and basal compartments
at 496 nm. The rate of permeation was determined by the ratio of
apical/basal fluorescence [33,34]. To determine whether blocking
uPAR will abrogate the permeability-inducing effect of VEGF and
CM, HUVECs were preincubated with 10 μm/ml anti-uPAR Ab
for 1 hour before adding VEGF or CM to the upper chambers.
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Immunofluorescence Staining of the Tight Junction Protein
Zona Occludens 1
At the beginning and at the indicated time points of the endothelial
permeability experiments described, HUVECs on filters were washed
three times with PBS and fixed in absolute methanol at −20°C
for 15minutes, permeabilized with 0.02%Tween 20 in PBS for 10min-
utes, and blockedwith 20%AquaBlock (East Coast Biologics, Inc,North
Berwick, MA) in PBS for 3 hours. Filters are then incubated with FITC–
zona occludens 1 (ZO-1) antibody (Chemicon, Millipore) diluted in
blocking buffer for 1 hour at room temperature. After further washing,
the filters aremountedwithVectashieldMountingMedium (Vector Lab,
Burlingame, CA) and examined under a fluorescent microscope.
Statistical Analysis
Kaplan-Meier curves, 2 × 2 Fisher exact test, and χ2 test and non-
parametric Wilcoxon-Mann-Whitney analysis of IP tumors and the
association of the expression of uPAR with histopathologic tumor
grade were evaluated using the nonparametric Wilcoxon-Mann-
Whitney and Kruskal-Wallis tests, performed using GraphPad Prism
5.0 (San Diego, CA). Differences were considered significant at P <
.05. All other data were analyzed by two-tailed Student’s t test and
one-way analysis of variance (ANOVA).
Results
Suppression of Peritoneal Ovarian Carcinomatosis in
uPAR−/− Mice
Using a syngeneic mouse model of peritoneal ovarian carcinomatosis
(POC) injecting ID8-GFP murine ovarian cancer cell line [26] in
uPAR−/−mice and their wild-type (uPAR+/+) littermates, we found pro-
longed survival (Figure 1A) and restrained tumor growth in uPAR−/−
mice compared with their wild-type counterparts. Disease progression
Figure 1. Effects of uPAR deficiency on ID8 intraperitoneal tumor growth. (A) Kaplan-Meier curve showing animal survival of uPAR+/+ and
uPAR−/− mice after IP injection of ID8-GFP cells (1 × 106 cells/500 μl PBS). (B) Tumor progression was monitored in the live animal by
girth measurement for 7 weeks after injection of ID8 cells. *P < .05 between indicated time points in uPAR+/+ and uPAR−/−, Student’s
t test. **P < .05 in uPAR+/+, one-way ANOVA. (C) Fluorescent photomicrographs (magnification, ×10) of representative IP tumor nodules
developing in uPAR+/+ and uPAR−/− (upper). Boxes (lower) represent mean ± SEM scores of peritoneal tumor nodules, and whiskers
represent the minimum and maximum values. ***P < .0001, non–two-tailed parametric Mann-Whitney test. (D) Ki67 immunostaining of
IP tumor nodules (magnification, ×200). Bars represent mean ± SEM of Ki67-positive nuclei counted in six random high-power fields
(proliferation index). *P < .001, Student’s t test.
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was slower in uPAR−/− mice as determined by measuring the girth of
live mice (Figure 1B). To compensate for widespread dissemination of
small tumor nodules in the peritoneal cavity and for the large tumor
nodules whose margins are difficult to distinguish, we adopted two in-
dependent arbitrary scoring systems for each mouse considering the
number and size of the visible tumor nodules, as earlier published
[26] and described in the Materials and Methods. The average score/
animal was calculated, and the means of the scores of animals in each
cohort were calculated (Figure 1C). This approach provided adequate
representation of the tumor burden. We also found that the number
of proliferating cells was significantly decreased in tumors developing
in uPAR−/− mice compared with their wild-types (Figure 1D). There
was no difference in the distribution of metastatic lesions between
uPAR−/− and their uPAR+/+ counterparts. In the latter, tumor nodules
not only grew on the mesothelium lining the peritoneal cavity but also
broke through the mesothelial layer into the submesothelial stroma.
Whereas in mice lacking uPAR, breaching the mesothelial layer and
submesothelial invasion were observed only in one animal in which
a few nodules broke through the mesothelial layer and invaded. It is
noteworthy to mention that only mesenteric lymph nodes were
involved in the uPAR+/+ mice.
Host uPAR Contributes to Inflammatory Environment
in POC
The incidence and volume of ascitic fluid accumulation were signifi-
cantly lower in uPAR−/− mice (Figure 2A). It is noteworthy to mention
that only two mice ascitic fluid volume correlated with the number
and size of IP tumor implants. Lower levels of proinflammatory cyto-
kines IL-6, CCL2, and VEGF (Figure 2B) were detected in uPAR−/−
mice compared with their wild-type counterparts. Consistently, F4/80
immunostaining of tumor sections revealed that TAMs were signifi-
cantly higher in wild-type compared with uPAR−/− mice (Figure 2C).
In addition, significantly lower levels of PGE2 and 8-isoprostane
(Figure 2D) as well as uPA activity (Figure 2E ) were detected in
uPAR−/− ascitic fluid. Moreover, the enzymatic activity of MMP-2
and MMP-9 were lower in uPAR−/− ascitic fluid (Figure 2F). Together,
these data indicate that the host uPAR suppresses tumor develop-
ment of peritoneal ID8 tumor implants and decreases accumulation
Figure 2. Absence of host uPAR is associated with decreased inflammation. (A) Scatterplots representing the incidence and volume of
ascitic fluid measured in both genotypes at the end of 7 weeks after ID8 injection. Values represent mean ± SEM. *P < .001, comparing
the incidence by χ2 test. **P < .05, compared with the tumor volume in uPAR−/− mice. (B) Levels of VEGF, IL-6, and CCL2 in the ascitic
fluid of uPAR+/+ and uPAR−/− mice. (C) TAMs were determined by F4/80 immunostaining of uPAR+/+ and uPAR−/− tumor tissues. Bars
represent means ± SEM of macrophages counted in six high-power fields (n = 3 each; magnifications, ×200). *P < .05, Student’s t test.
(D) Levels of PGE2 and 8-isoprostane were measured by enzyme immunoassay. (E) uPA activity in the ascetic fluid was determined as
described in Materials and Methods. Bars represent means ± SEM of three representative experiments performed in triplicates. *P < .05,
Student’s t test. (F) Gelatin zymography of uPAR+/+ and uPAR−/− ascitic fluids.
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malignant ascitic fluid concomitant with decreased infiltration of
macrophages, inflammatory, and proteolytic activity.
Effect of uPAR on Ovarian Cancer Cell Interaction with
Mesothelial Cells
We next sought to explain the effect of host uPAR on the develop-
ment of IP ovarian tumors and to determine the contribution of the
different cell types in the peritoneal microenvironment and their rele-
vance to human disease. We and others [2,3,6,14,26,27,29,30,32,35]
have reported that the first step in the development of POC is adhesion
of the shed ovarian cancer cells to mesothelial cells lining the peritoneal
cavity. In addition, we have earlier reported that coculture of ovarian
cancer cells with mesothelial cells induces the expression and secretion
of proinflammatory cytokines and mediators in the peritoneal milieu
and in turn activates mesothelial cells to support further cancer cell
adhesion [14,27,30]. To determine the role mesothelial uPAR in their
interactions with cancer cells, we knocked down uPAR in human
mesothelial cells and tested their ability to allow ovarian cancer cell
adhesion. We found that knockdown of uPAR in mesothelial cells
inhibited ovarian cancer cell adhesion (Figure 3A). We next determined
Figure 3. Effects of mesothelial uPAR on mesothelial-ovarian cancer cell interactions. (A) Western blot shows the effective knockdown
of uPAR in Meso301 cell line and tubulin as a loading control. CMFDA-labeled UMUC3, OVCAR3, and CAOV3 were allowed to adhere to
confluent monolayers of Meso301 depleted or not of uPAR expression by siRNA (si uPAR) or scrambled control (scr) in 24-well plates for
6 hours. In one set of experiments, mesothelial cells were treated with 10 μg/ml uPAR neutralizing antibody for 2 hours before and
during incubation with cancer cells. After washing nonadherent cells, cancer cell adhesion was determined by measuring the fluores-
cent intensity at A488. Bars represent the means ± SEM of three independent experiments performed in triplicates. *P < .05, between
adhesion to scr and si uPAR Meso301. **P < .05 between scr and uPAR Ab-treated cells, Student’s t test. (B) Meso301 cells were
cotransfected with pNFκB luc, si uPAR, and scr siRNA 48 hours before coincubation with cancer cells or treatment with uPAR for a
further 24 hours. NF-κB activation was determined by measuring the luciferase activity of cell lysates. Bars represent the means ± SEM
of three independent experiments performed in triplicates. *P < .05, between Meso301scr cells and si uPAR or uPAR Ab in single
culture or coculture. **P < .05 between Meso301 in single culture and coculture. (C) The levels of VEGF, IL-6, and CCL2 in Meso301
depleted or not of uPAR in single culture and coculture with ovarian cancer cells were determined by quantitative reverse transcription–
polymerase chain reaction and were normalized to GAPDH. Bars represent the means ± SEM of normalized levels of three independent
experiments performed in duplicates. *P < .05, between Meso301scr cells and si uPAR.
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whether adhesion of ovarian cancer cells to mesothelial cells triggers
the activation of nuclear factor κB (NF-κB)—the key orchestrator of
cancer-associated inflammation. We transfected mesothelial cells with
NF-κB luciferase reporter after knockdown of uPAR and cocultured
them with ovarian cancer cells for 24 hours. We found that knock-
down of uPAR in mesothelial cells suppressed NF-κB activation in
mesothelial cells whether they were cultured alone or cocultured with
SKOV3, OVCAR3, and CAOV3 (Figure 3B). Furthermore, uPAR
knockdown in mesothelial cells decreased the basal and coculture-
induced up-regulation of inflammatory cytokines VEGF, IL-6, and
CCL2 (Figure 3C) that have been shown to support ovarian cancer
cell adhesion [14,30].
Effect of uPAR on Vascular Permeability
The increase in vascular permeability is a hallmark of ovarian
cancer because it leads to the formation of extensive ascites in the
earlier and later stages of the disease. Several studies have indicated
that vascular endothelial growth factor (VEGF), also known as vas-
cular permeability factor, is implicated in ascites formation, par-
ticularly in ovarian cancer [36,37]. Endothelial uPAR has been
implicated in VEGF-mediated vascular permeability in vitro and
in vivo [23,24,38]. Despite the recent reports of the effect of uPAR
blockade by antibodies in ameliorating in vivo tumor growth of
CAOV3 cells in nude mice [6], the effect of endothelial uPAR on
vascular permeability and ascites formation is not elucidated. To
determine whether endothelial cell uPAR affects their permeability,
we knocked down uPAR in HUVECs and allowed them to grow to
confluence on transwell filters. We tested the effect of VEGF (Fig-
ure 4A) and CM of SKOV3, OVCAR3, and CAOV3 ovarian cancer
cell lines (Figure 4, B-D) on the paracellular flux of FITC-dextran
through HUVECs monolayers. We found that VEGF-induced dis-
ruption of the endothelial tight junctions as determined by ZO-1
immunostaining of HUVECs monolayers was associated with in-
creased FITC-dextran in the bottom chambers of the transwells
and decreased apical/basal ratio and that this effect was mitigated
by knocking down endothelial uPAR (Figure 5). Similar effects of
FITC-dextran apical/basal flux were observed with CM of SKOV3,
OVCAR3, and CAOV3 cells and were inhibited by the knockdown
of endothelial uPAR. Treating HUVECs with anti–uPAR-neutralizing
antibody had partially antagonized the permeability-inducing effect of
VEGF and CM of ovarian cancer cells (Figure W1). To determine the
in vivo specificity of uPAR and VEGF interactions, we injected ID8
cells stably expressing VEGF [25,27] IP in uPAR+/+ and uPAR−/− mice
and monitored tumor progression as described above. We found that,
despite constitutive overexpression of VEGF in ID8 cells, the accumu-
lation of ascitic fluid in uPAR−/− mice was significantly lower than that
in uPAR+/+, concomitant with slower disease progression and longer
median animal survival (Figure W2).
Figure 4. Effect of uPAR on vascular permeability. Confluent monolayers of HUVECs depleted or not of uPAR (scr and si-uPAR) were
grown on transparent 0.4-μm filters for 48 hours and were apically treated with (A) VEGF (40 μg/ml) or 72-hour CM of (B) SKOV3,
(C) OVCAR3, and (D) CAOV3 added apically on the top chamber of the transwells. The integrity of the endothelial barrier was determined
by measuring the flux of FITC-dextran before and at the indicated times after treatment of HUVECs. Line graphs represent the mean ±
SEM of the apical/basal fluorescence of the aliquots of collected from apical and basal chambers of the transwells. *P < .05, compar-
ing the decrease in apical/basal flux in VEGF- or CM-treated scr control, one-way ANOVA. **P < .01, comparing the apical/basal flux
between VEGF- or CM-treated scr control and si uPAR HUVECs, Student’s t test.
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Genetic Ablation and Neutralization of Macrophage uPAR
Inhibited Their In Vitro Interactions with Cancer Cells
TAMs have been shown to contribute to the inflammatory micro-
environment in ovarian cancer and were associated with poor prognosis
[35,39,40]. We and others have previously shown that macrophages
increase the invasive phenotype of ovarian cancer cells and contribute
to augmented production of inflammatory mediators in vitro and
in vivo. In addition, macrophages contributed to increased proteolytic
activity of MMP-2 and MMP-9 as well as uPA activity when co-
cultured of ovarian cancer cells [14,26,27,29,30,39–41]. Furthermore,
impaired growth of prostate cancer cells in uPAR−/− and uPA−/− mice
was associated with decreased macrophage infiltration and decreased
cancer cell invasiveness [8]. To further investigate the roles of the
uPA/uPAR axis in macrophage chemotaxis in vitro, we found that
depletion of uPAR in human U937 macrophages suppressed their
ability to migrate toward CM from SKOV3, CAOV3, and OVCAR3
cells (Figure 6A). Consistently, uPAR-depleted U937 cells exhibited
decreased ability to induce SKOV3, CAOV3, and OVCAR3 cells’ in-
vasiveness (Figure 6B). Similar effect was noticed by neutralization of
uPAR by a neutralizing antibody (Figure 6C ). We next determined
whether macrophage uPAR is involved in the activation of NF-κB in-
duced by their coculture with ovarian cancer cells, we transfected U937
cells with NF-κB luciferase reporter after knockdown of uPAR and
cocultured them with ovarian cancer cells for 24 hours and found
that knockdown of uPAR in U937 cells suppressed NF-κB activation
whether they were cultured alone or cocultured with SKOV3, OVCAR3,
and CAOV3 (Figure 6D).
Expression of uPAR in Human Ovarian Tumors
Previous studies have reported various expression levels of uPAR in
ovarian cancer (summarized in Kenny et al. [6]). In their comprehen-
sive study, Kenny et al. [6] reported the expression of uPAR in 92% of
patients with ovarian cancer with a stronger expression in the cancerous
epithelium than the stroma and absent or low in normal ovarian sur-
face epithelium. Although uPAR expression was found to be indepen-
dent of the classic clinicopathologic parameters, platinum sensitivity,
or patients’ survival, they reported they reported the efficiency of block-
ing uPAR in inhibiting ovarian cancer cell adhesion and invasion
in vitro and in vivo. Together with the earlier reports that uPAR is
elevated in tumors, serum, and ascitic fluid as well as our in vivo and
in vitro findings, we sought to analyze uPAR expression in human
ovarian tumors taking into account the tumor heterogeneity, stromal
uPAR, as well as the different grades. We adopted a scoring system
that combined the intensity and the frequency of staining and allowed
to distinguish stromal from tumor uPAR (Figure 7A). In accord with
earlier reports [6], we found lower levels of uPAR in normal ovarian
tissues, both epithelium and stroma. The hypothesis is that the proba-
bility of the increase in the level of uPAR in early tumor stages precedes
the increase in intensity and frequency of distribution in tumors. The
Figure 5. Effect of uPAR of endothelial tight junctions. Confluent monolayers of HUVECs were grown and treated as described in
Figure 4. At the end of 6 hours, filters were fixed and immunostained for ZO-1, mounted in fluorescence mounting medium, and were
analyzed by fluorescence microscopy. Total magnification, ×400. Images are representative of at three filters/each condition.
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expression levels of uPAR were significantly higher in cancerous epi-
thelium (Figure 7B), and juxtatumoral stroma (Figure 7C). Comparing
uPAR tumor and stromal composite expression scores between normal
and each grade was significant when analyzed by Kruskal-Wallis test
and receiver operating characteristic curve. In addition, when com-
paring, the tumor grades were significant when analyzed by Kruskal-
Wallis test and the Dunn post hoc test; the correlation between uPAR
scores among different grades was insignificant.
Together, these data indicate that the utility of uPAR as a prog-
nostic marker in ovarian cancer may vary among the different studies
owing to technical analytical variables.
Discussion
uPAR has been reported as a tumor promoter in several solid cancers
through a mitogenic, proinvasive effect on cancer cells [6,7,11,22,42,
43]. In addition, genetic manipulation of uPAR in tumor cells or
functional neutralization by neutralizing antibodies demonstrated its
importance as a therapeutic target [6,7,11,22,42,43]. However, to date,
the mechanistic role of host uPAR in ovarian cancer progression and
development of peritoneal implants and malignant ascitic fluid has
not been shown. In addition, because uPAR can be produced by both
the tumor and the host, the contributions of each of these compart-
ments to ovarian cancer progression have not been defined. However,
the contribution of host-derived uPAR on ovarian cancer development
and development of recalcitrant recurrent disease remains unclear.
In the current study, we systematically demonstrated the role of
host uPAR in ovarian cancer. Using a syngeneic ovarian cancer model
in uPAR+/+ and uPAR−/−mice, we found that tumor take, growth, pro-
gression, and median animal survival were dramatically diminished
in uPAR−/− mice compared with uPAR+/+ controls. Consistently, we
found decreased proliferation of tumor cells in uPAR−/−mice compared
with their uPAR+/+. This was expected because of the impairment of
Figure 6. Effects of uPAR deficiency onmacrophage chemotaxis. (A) Western blot shows the effective knockdown of uPAR in U937macro-
phages with tubulin as a loading control. (B) In vitro chemotaxis assays of U937 cells depleted or not of uPAR through Matrigel-coated
3-μm filters toward 72-hour CM of SKOV3, OVCAR3, and CAOV3 cells as described in Materials and Methods. (C) SKOV3, OVCAR3, and
OVCAR3 were allowed to invade Matrigel-coated 8-μm inserts toward CM from U937-scr and U937-si uPAR for 5 hours. As a control, a
blocking uPAR Ab (10 μg/ml) was used. Bars represent mean ± SEM of counted invading/attracted cells of three independent experiments
performed in triplicates. *P< .01, compared with control scr-U937 cells, Student’s t test. (D) U937 cells were cotransfected with pNFκB luc,
si uPAR, and scr siRNA 48 hours before coculture with subconfluent monolayers of ovarian cancer cells grown in 24 wells. U937 (1 × 106)
cells were added on 0.4-μm filters without cell-cell contact or treatment with uPAR for further 24 hours. NF-κB activation was determined
by measuring the luciferase activity of cell lysates. Bars represent the means ± SEM of three independent experiments performed in
triplicates. *P < .05, between U937- scr cells and si uPAR or uPAR Ab in single culture and coculture. **P < .05, between U937 cells in
single culture and coculture.
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survival signaling cascades activated by the interaction of uPAR with
integrins, growth factor receptors, and ECM molecules [6,7,11,
22,42,43], which has been shown to be crucial for ovarian cancer
progression (reviewed in Lengyel [2] and Kenny et al. [6]).
In addition, tumors in uPAR−/− mice displayed significantly less
infiltrating TAMs, ascitic fluid volume, as well as the levels of VEGF,
CCL2, and IL-6 in the ascitic fluid. These three factors, in particular,
have been linked to the aggressiveness of the human ovarian cancer
as well as the recurrence and chemoresistance, with accumulation
of large volumes of ascitic fluid [2,12,13,44–47]. In addition to
its putative potent angiogenic function, VEGF is also responsible
for vascular permeability and formation of malignant ascites
[36,37,48]. Similarly, the proinflammatory cytokines IL-6 and
CCL2 are not only implicated in recruitment and activation of
TAM but also are shown to exert potent mitogenic, proinvasive,
and angiogenic effects in many cancers including ovarian cancer
[12,14,27,30,31,40,42,46,47]. Furthermore, IL-6 and CCL2 were
implicated in disruption or epithelial and endothelial barriers
in microvascular and pulmonary diseases [49,50]. Moreover, the
decreased levels of PGE2 and 8-isoprostane together with de-
creased proteolytic activity of uPA, MMP-2, and MMP-9 in uPAR−/−
mice compared with their uPAR+/+ controls further explain the
decreased in vivo tumor growth and accumulation of ascitic fluid.
Interestingly, these factors are downstream of as well as activators of
NF-κB—the key orchestrator of inflammation and ovarian cancer
progression [13,44].
Our in vivo and in vitro findings reveal that knockdown of uPAR in
mesothelial cells did not support SKOV3, OVCAR3, and CAOV3
cell adhesion, suggesting impaired interactions of uPAR, with integrins
and ECM proteins such as vitronectin, fibronectin, and laminin 5
that are overexpressed in invasive cancer cells [51–54]. In addition,
depletion of uPAR in mesothelial cells attenuated their basal and can-
cer cell–induced NF-κB activation with a subsequent decrease in
coculture-induced VEGF, IL-6, and CCL2 levels that are implicated
not only in chemotaxis of tumor cells toward mesothelial cells but also
in survival, adhesion, invasiveness, and angiogenesis [14,27,30,31,52].
Herein, we also provide evidence that endothelial uPAR plays an
important role in the accumulation of ascitic fluid. We show that
depletion of endothelial uPAR mitigates the permeability-inducing
effect of VEGF as well as that of CM of ovarian cancer cells and that
it was mediated, in part, through maintaining the integrity of the tight
junction protein ZO-1. The antagonistic effect of uPAR on VEGF-
induced vascular permeability was further supported in vivo by de-
creased accumulation of ascitic fluid in uPAR−/− injected with ID8 cells
stably overexpressing VEGF compared with accumulation in uPAR+/+.
These observations may provide an explanation of the increased levels
of serum and ascitic fluid uPAR in patients with advanced ovarian
cancer [52,55–58].
Figure 7. uPAR expression in normal and cancerous ovarian tissues. (A) Immunostaining of uPAR in human ovarian cancer and normal
ovarian tissues TMAs (magnification, ×200). (B and C) The two arbitrary scores for intensity and frequency of uPAR immunostaining in
the indicated groups of tumor (B) and stromal (C) compartments and normal tissues were transformed into composite expression scores
as described in the Materials and Methods. Boxes represent the mean ± SEM with whiskers minimum and maximum scores for each
group. *Correlation of composite scores in association with tumor grades by one-way ANOVA. **Correlation of composite scores between
indicated groups by one-way ANOVA with Bonferroni multiple comparison test and receiver operating characteristic curve.
268 Role of uPAR in Ovarian Cancer Al-Hassan et al. Neoplasia Vol. 14, No. 4, 2012
Furthermore, genetic ablation of macrophage uPAR impaired
macrophage recruitment to the developing in vivo tumors (TAM), their
ability to migrate toward CM of cancer cells, as well as the ability of
their secretome to induce cancer cell invasiveness in vitro [15]—a
process that involves activation of NF-κB in macrophages [52] with
smoldering cancer inflammation and progression.
In conclusion, our results showed that host uPAR augments ovarian
cancer cell proliferation, mesothelial adhesion, and invasiveness. More-
over, mesothelial and macrophage uPARs modulate their interactions
with cancer cells. These results suggest a novel mechanism for the
regulation of uPAR-induced cellular functions that may extend its
therapeutic targeting in ovarian cancer to minimize the toxicity of
standard-of-care therapies. Given the limited and often controversial
effects of VEGF-based therapies, targeting uPAR as a downstream ef-
fector of VEGF-induced vascular permeability may provide beneficial
advantage to inhibit the formation of ascites.
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Figure W1. Neutralization of uPAR inhibits vascular permeability. Confluent monolayers of HUVECs were grown on transparent 0.4-μm
filters for 48 hours and were pretreated with 10 μg/ml anti–uPAR-neutralizing antibody or isotype IgG control for an hour before apical
treatment with (A) VEGF (40 μg/ml) or 72-hour CM of (B) SKOV3, (C) OVCAR3, and (D) CAOV3 added apically on the top chamber of the
transwells. The integrity of the endothelial barrier was determined by measuring the flux of FITC-dextran before and at the indicated
times after treatment of HUVECs. Line graphs represent the mean ± SEM of the apical/basal fluorescence of the aliquots of collected
from apical and basal chambers of the transwells. *P < .05, comparing the decrease in apical/basal flux in VEGF or CM treatment from
0 to 6 hours, one-way ANOVA. **P < .01, comparing the apical/basal flux between VEGF- or CM-treated and anti-uPAR antibody,
Student’s t test.
Figure W2. uPAR deficiency inhibits VEGF-induced intraperitoneal
tumor growth and ascites fluid. (A) Scatterplots representing the
incidence and volume of ascitic fluid measured in both genotypes
at the end of 5 weeks after ID8 VEGF injection. Values represent
mean ± SEM. *P < .001, comparing ascitic fluid volume between
uPAR−/− and uPAR+/+ mice. (B) Kaplan-Meier curve showing animal
survival of uPAR+/+ and uPAR−/−mice after IP injection of ID8-VEGF
cells (1 × 106 cells/500 μl PBS).
